GENE ONLINE|News &
Opinion
Blog

2021-10-07| In-DepthSpecial

Expanding Deals and Investments Underscore Burgeoning Market of Targeted Protein Degradation

by Rajaneesh K. Gopinath
Share To
As opposed to large molecule biologics such as monoclonal antibodies, vaccines, or other proteins, small molecule drugs offer several advantages. Their small size, low immunogenicity, easy permeability, and most importantly, a simple and stable structure allow them to hit a therapeutic target better. Also, they are easily convertible to the oral form, and they are very cost-effective.

The biopharma industry spends millions on small molecule drug discovery, and forecasters estimate that the market will reach $50,823.06 million in value by 2027. However, the process of bringing small molecule drugs to the clinic is long, even though their manufacturing is relatively simple.

In addition to the technical challenges, often, only one out of every 10,000 compounds go on to obtain regulatory approval. Therefore, as opposed to the conventional drugs that block protein activity, the industry is now pursuing a new type of small molecule known as “Targeted protein degraders”. This exciting technology has become a hot commodity for drug discovery, giving way to large deal-making between companies and the launch of new startups that are racking in the big bucks.

GO Prime with only $1.49 now

LATEST
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
Discover the Next Billion-Dollar Unicorn at the Biotech Innovation Funding Networking Event
2024-03-21
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top